Teladoc Health AI Price Prediction

Teladoc Health remains unprofitable, as reflected in its negative EPS and PE ratio. While the company likely maintains meaningful revenue scale, the current earnings profile suggests ongoing operating or restructuring challenges and limited near‑term visibility to sustainable profitability.

• Negative EPS of -1.22 and a PE ratio of -6.35 indicate the company is still loss-making, with equity investors effectively funding ongoing operating losses.
• The valuation multiple implied by a negative PE, combined with a depressed share price, suggests the market is skeptical about the pace and certainty of Teladoc’s path to profitability.
• Without evidence of improving margins or positive net income trends, the financial profile points to elevated execution risk and a need for either cost rationalization or stronger revenue growth to justify equity value.

Despite a strong 16% gain over the last month, Teladoc’s share price at $7.72 trades dramatically below its 200-day moving average of $20.80, signaling a longer-term downtrend. The RSI near 64 shows short-term momentum is positive but approaching overbought territory within a structurally weak technical setup.

• Current price of $7.72 is far under the 200-day moving average of $20.80, indicating the stock remains in a pronounced long-term downtrend despite recent upside.
• RSI of 64.42 reflects strong recent buying pressure and short-term bullish momentum, but it is nearing the overbought zone (typically >70), which can precede consolidation or pullbacks.
• The combination of a deeply broken longer-term trend with a sharp recent bounce suggests the move may be more of a short-covering or relief rally than a confirmed trend reversal.

Teladoc Health’s stock shows short-term positive momentum but remains structurally weak given its deep discount to the 200-day moving average and ongoing lack of profitability. Alternative data reflects a stable but not rapidly expanding user ecosystem, which, combined with a hiring slowdown, tempers the growth narrative. Overall, the balance of evidence leans bearish, with recent gains looking more like a tactical bounce than a confirmed fundamental turnaround.

• Persistent negative earnings and a share price far below the long-term moving average point to continued fundamental and technical pressure on the stock.
• Stable engagement and app activity are positives, but flat growth in downloads and reduced hiring suggest a cautious operating stance rather than aggressive expansion.